Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MDK | P21741 | 3/20 | 0.41 |
| ▸ | BDNF | P23560 | 3/20 | 0.41 |
| ▸ | PTN | P21246 | 2/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19325099 | 1.00 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL21908706 | 0.94 | LGALS3 (0.41) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL20290392 | 0.91 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL18608138 | 0.91 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL18608226 | 0.91 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL23322444 | 0.91 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL22272475 | 0.91 | BDNF (0.40) | LGALS3LGALS8LGALS4MDKBDNF | |
| SCHEMBL21316642 | 0.90 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL22472735 | 0.90 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1MDK | |
| SCHEMBL18737220 | 0.90 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311472-B2 | Topical composition comprising crosslinked hyaluronic acid and a polyacrylate compound | TEOXANE (CH) | 2022-04-26 | — | — | US | disclosed |
| US-11091566-B2 | Methods for the production of biopolymers with defined average molecular weight | MEDSKIN SOLUTIONS DR. SUWELACK AG (DE) | 2021-08-17 | — | — | US | disclosed |
| US-20210244644-A1 | TOPICAL COMPOSITION COMPRISING CROSSLINKED HYALURONIC ACID AND A POLYACRYLATE COMPOUND | TEOXANE (CH) | 2021-08-12 | — | — | US | disclosed |
| US-10976324-B2 | Synergistic combination of biomarkers for detecting and assessing hepatic fibrosis | UNIVERSITÉ PARIS CITÉ (FR) | 2021-04-13 | — | — | US | disclosed |
| US-20210052477-A1 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | ALLUSTRA TECHNOLOGIES LLC | 2021-02-25 | — | — | US | disclosed |
| US-10632081-B2 | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-04-28 | — | — | US | disclosed |
| US-20180078490-A1 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | ALLUSTRA TECHNOLOGIES LLC | 2018-03-22 | — | — | US | disclosed |
| US-20170160289-A1 | SYNERGISTIC COMBINATION OF BIOMARKERS FOR DETECTING AND ASSESSING HEPATIC FIBROSIS | BIO-RAD INNOVATIONS (FR) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078490-A1 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | CUTA, FABP4, PLOD3 | LGALS3 1148/4885LGALS8 2792/4885LGALS4 807/4885 |
| US-20210244644-A1 | TOPICAL COMPOSITION COMPRISING CROSSLINKED HYALURONIC ACID AND A POLYACRYLATE COMPOUND | CUTA, CD44, COL14A1 | LGALS3 466/4885LGALS8 808/4885LGALS4 387/4885 |
| US-10632081-B2 | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | DLST, CD44, DACH1 | LGALS3 1138/4885LGALS8 2104/4885LGALS4 1374/4885 |
| US-20210052477-A1 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | CUTA, COL14A1, GLA | LGALS3 631/4885LGALS8 1236/4885LGALS4 498/4885 |
| US-11091566-B2 | Methods for the production of biopolymers with defined average molecular weight | ALG1, MGAM, LGALS3 | LGALS3 3/4885LGALS8 30/4885LGALS4 4/4885 |
| US-11311472-B2 | Topical composition comprising crosslinked hyaluronic acid and a polyacrylate compound | CUTA, CD44, COL14A1 | LGALS3 466/4885LGALS8 808/4885LGALS4 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.